Literature DB >> 26767050

Bioinformatics analysis and expression study of fumarate hydratase in lung cancer.

Zongjuan Ming1, Meihua Jiang1, Wei Li1, Na Fan1, Wenjing Deng1, Yujie Zhong1, Yuping Zhang1, Qiuhong Zhang1, Shuanying Yang1.   

Abstract

BACKGROUND: As its etiology and pathogenesis is obscure, illustrating the molecular mechanism of lung cancer has become a serious and urgent task. Studies have shown that fumarate hydratase (FH) is a tumor suppressor related to tumorigenesis, development, and invasion. Our aim was to analyze the biological information of FH, and detect the messenger ribonucleic acid (mRNA) and protein expression of FH in lung cancer cells to explore its role in tumorigenesis and in the development of lung cancer.
METHOD: We analyzed the biological characteristics of FH, then utilized reverse transcription-polymerase chain reaction (RT-PCR) to study FH mRNA expression in A549 and 16 human bronchial epithelial (HBE) cell lines. The protein expression of FH was detected in 57 cases of human lung cancer tissues and 19 cases of normal lung tissues by immunohistochemistry.
RESULTS: 1. Bioinformatic analysis: FH mainly exist in the mitochondria; the common structural elements of FH are mainly α-helix, random coil, β-turn, and extended strand; there are five possible transmembrane domains in the entire polypeptide chain; FH is a hydrophilic and soluble protein. 2. RT-PCR result: FH mRNA expression was downregulated in A549 cells compared with 16HBE cells. 3. Immunohistochemistry: FH protein expression was significantly lower in lung cancer cells than in normal lung tissues (P < 0.05), but was not correlated with the patients' age, gender, tumor size, pathological type, or lymph node, distant, or tumor node metastasis stage.
CONCLUSION: FH was under-expressed in lung cancer, suggesting that it may be an indicator of tumorigenesis and could be a potential target for therapies against lung cancer in the future.

Entities:  

Keywords:  Bioinformatics; expression; fumarate hydratase; lung cancer

Year:  2014        PMID: 26767050      PMCID: PMC4704329          DOI: 10.1111/1759-7714.12127

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN: 1759-7706            Impact factor:   3.500


  31 in total

1.  Inherited susceptibility to uterine leiomyomas and renal cell cancer.

Authors:  V Launonen; O Vierimaa; M Kiuru; J Isola; S Roth; E Pukkala; P Sistonen; R Herva; L A Aaltonen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

2.  Clinical features of multiple cutaneous and uterine leiomyomatosis: an underdiagnosed tumor syndrome.

Authors:  N Afrina Alam; Ella Barclay; Andrew J Rowan; Jonathan P Tyrer; Eduardo Calonje; Sanjiv Manek; David Kelsell; Irene Leigh; Simon Olpin; Ian P M Tomlinson
Journal:  Arch Dermatol       Date:  2005-02

3.  Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers.

Authors:  J Geradts; K M Fong; P V Zimmerman; R Maynard; J D Minna
Journal:  Clin Cancer Res       Date:  1999-04       Impact factor: 12.531

4.  ras p21 expression in the progression of breast cancer.

Authors:  F B Fromowitz; M V Viola; S Chao; S Oravez; Y Mishriki; G Finkel; R Grimson; J Lundy
Journal:  Hum Pathol       Date:  1987-12       Impact factor: 3.466

5.  Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer.

Authors:  Ian P M Tomlinson; N Afrina Alam; Andrew J Rowan; Ella Barclay; Emma E M Jaeger; David Kelsell; Irene Leigh; Patricia Gorman; Hanan Lamlum; Shamima Rahman; Rebecca R Roylance; Simon Olpin; Stephen Bevan; Karen Barker; Nicholas Hearle; Richard S Houlston; Maija Kiuru; Rainer Lehtonen; Auli Karhu; Susa Vilkki; Päivi Laiho; Carita Eklund; Outi Vierimaa; Kristiina Aittomäki; Marja Hietala; Pertti Sistonen; Anders Paetau; Reijo Salovaara; Riitta Herva; Virpi Launonen; Lauri A Aaltonen
Journal:  Nat Genet       Date:  2002-02-25       Impact factor: 38.330

6.  UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.

Authors:  Youfeng Yang; Vladimir A Valera; Hesed M Padilla-Nash; Carole Sourbier; Cathy D Vocke; Manish A Vira; Mones S Abu-Asab; Gennady Bratslavsky; Maria Tsokos; Maria J Merino; Peter A Pinto; Ramaprasad Srinivasan; Thomas Ried; Len Neckers; W Marston Linehan
Journal:  Cancer Genet Cytogenet       Date:  2010-01-01

Review 7.  Genetic basis of cancer of the kidney: disease-specific approaches to therapy.

Authors:  W Marston Linehan; James Vasselli; Ramaprasad Srinivasan; McClellan M Walther; Maria Merino; Peter Choyke; Cathy Vocke; Laura Schmidt; Jennifer S Isaacs; Gladys Glenn; Jorge Toro; Berton Zbar; Donald Bottaro; Len Neckers
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

Review 8.  Molecular genetics and mechanisms of apoptosis in carcinomas of the lung and pleura: therapeutic targets.

Authors:  L R Motadi; N L Misso; Z Dlamini; K D Bhoola
Journal:  Int Immunopharmacol       Date:  2007-07-31       Impact factor: 4.932

Review 9.  Mutant metabolic enzymes are at the origin of gliomas.

Authors:  Hai Yan; Darell D Bigner; Victor Velculescu; D Williams Parsons
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 13.312

Review 10.  HIF and fumarate hydratase in renal cancer.

Authors:  S Sudarshan; W M Linehan; L Neckers
Journal:  Br J Cancer       Date:  2007-01-09       Impact factor: 7.640

View more
  3 in total

1.  Quantitative proteomic analysis of the miR-148a-associated mechanisms of metastasis in non-small cell lung cancer.

Authors:  Dandan Chu; Jing Li; Hechun Lin; Xiao Zhang; Hongyu Pan; Lei Liu; Tao Yu; Mingxia Yan; Ming Yao
Journal:  Oncol Lett       Date:  2018-04-26       Impact factor: 2.967

2.  The possible molecular regulation mechanism of CIK cells inhibiting the proliferation of Human Lung Adenocarcinoma NCL-H157 Cells.

Authors:  Dengrui Li; Yonghui Yang; Li Gao; Sumin Guo; Li Hui; Guiyun Zhu; Hongwei Hou; Shucai Wu
Journal:  Open Med (Wars)       Date:  2016-02-19

3.  Optimization of endothelial growth factor receptor monoclonal antibody-gold nanorods photothermal therapy for laryngeal squamous cell carcinoma.

Authors:  Yun Hai; Hao Wang; Youyu Qiu; Renchao Huang; Liufang Zhao; Hongyang Xu; Zichen Dong; Lu Zhang; Weidi Sun; Shiwen Zhang
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.